Interní Med. 2013; 15(10): 314-317

Eruptive xanthomatosis as first manifestation of diabetes mellitus

doc.MUDr.David Karásek, Ph.D.1, prof.MUDr.Helena Vaverková, CSc.1, Ing.Dalibor Novotný, Ph.D.2
1 III. interní klinika &ndash, nefrologie, revmatologie a endokrinologie LF UP a FN Olomouc
2 Oddělení klinické biochemie FN Olomouc

The authors describe a patient who displayed eruptive xanthomatosis as a manifestation of severe mixed dyslipidemia. Type 2 diabetes

mellitus was newly diagnosed in the patient. In addition to insulin resistance in abdominal obesity and an excessive fat intake the genetic

predisposition probably contributed to the development of dyslipidemia too. The patient was identified as a carrier for ε4 allele of the

gene for apolipoprotein E. Treatment of dyslipidemia and diabetes led to metabolic compensation and complete regression of skin lesions.

Keywords: eruptive xanthomatosis, diabetic dyslipidemia, insulin resistance, apolipoprotein E

Published: October 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karásek D, Vaverková H, Novotný D. Eruptive xanthomatosis as first manifestation of diabetes mellitus. Interní Med. 2013;15(10):314-317.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zadák Z. Kožní projevy hyperlipidemie u diabetiků z pohledu internisty. Vnitř Lék 2006; 52: 465-469. Go to PubMed...
    2. Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med 2008; 121: 10-12. Go to original source... Go to PubMed...
    3. Péče o nemocné s cukrovkou. ÚZIS 2011; http://www.uzis.cz/publikace/pece-nemocne-cukrovkou-2011.
    4. Doporučený postup péče o nemocné s diabetes mellitus 2. typu. DMEV 2012; 15: 13-18.
    5. Zadák Z, Tichý M, Mělka O. Vliv chylozity séra na výsledky některých biochemických vyšetření. Biochem Clin Bohemoslov 1987; 16: 251-259.
    6. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971-980. Go to original source... Go to PubMed...
    7. Karásek D, Vaverková H. Smíšená dyslipidemie - současné možnosti léčby. Interni Med 2011; 13: 7-12.
    8. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins-an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276: 273-281 concl. Go to original source... Go to PubMed...
    9. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628. Go to original source...
    10. von Eynatten M, Schneider JG, Humpert PM, et el. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004; 27: 2925-2929. Go to original source... Go to PubMed...
    11. Ghiselli G, Schaefer EJ, Zech LA, et al. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J Clin Invest 1982; 70: 474-477. Go to original source... Go to PubMed...
    12. Fumeron F, Rigaud D, Bertiere MC, et al. Association of apolipoprotein epsilon 4 allele with hypertriglyceridemia in obesity. Clin Genet 1988; 34: 258-264. Go to original source... Go to PubMed...
    13. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992; 33: 447-454. Go to original source...
    14. Chaudhary R, Likidlilid A, Peerapatdit T, et al. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol 2012; 11: 36. Go to original source... Go to PubMed...
    15. Shinozaki S, Itabashi N, Rokkaku K, et al. Diabetic lipemia with eruptive xanthomatosis in a lean young female with apolipoprotein E4/4. Diabetes Res Clin Pract 2005; 70: 183-192. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.